Innovative disease modifying treatment for Parkinson's patients
SynuCa Therapeutics combines decades of groundbreaking research in P-type ATPases and neuroscience from Aarhus University to propose a novel disease-modifying treatment for patients suffering from Parkinson's Disease and associated disorders.
By targeting the SERCA calcium transporter, our first-in-class small molecules salvage the root disease cause by repairing the neuronal calcium imbalances caused by pathological α-Synuclein brain species.
Photo: Esben Zøllner Olesen for BioInnovation Institute
Management
Lasse Reimer
CEO/Founder
William Dalby Brown
COO/founder
Professor Poul Henning Jensen
Founder
Professor Claus Elsborg Olesen